SCHEMBL2382196

SCHEMBL2382196

CCOC(=O)/C(=C\N(C)C)c1ccc(Br)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
S1PR4 O95977 1/20 0.45
MAPT P10636 1/20 0.45
S1PR1 P21453 1/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 4/20 0.40
GPR35 Q9HC97 1/20 0.40
TSHR P16473 2/20 0.40
HPGD P15428 4/20 0.39
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP4F2 P78329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2382197 1.00 LMNA (0.45) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL3411086 0.89 MEN1 (0.47) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL3411087 0.89 MEN1 (0.47) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL10475316 0.89 MEN1 (0.47) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL24252816 0.82 MEN1 (0.49) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL30451233 0.82 MEN1 (0.49) LMNANPSR1MEN1KMT2AS1PR4
SCHEMBL16110295 0.81 CYP11B1 (0.45) ALDH1A1GPR35HPGDCYP11B1CYP11B2
SCHEMBL16110296 0.81 CYP11B1 (0.45) ALDH1A1GPR35HPGDCYP11B1CYP11B2
SCHEMBL4770768 0.81 ALDH1A1 (0.46) LMNAMEN1KMT2AMAPTMAPK1
SCHEMBL4770761 0.81 ALDH1A1 (0.46) LMNAMEN1KMT2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012991-B2 3-(2,4-dimethoxyphenyl)-1,9-dimethyl-2-oxo-2,9-dihydro-1H-pyrido[2,3-b]indole-6-carboxylic acid; gamma-aminobutyric acid modulator; anticarcinogenic, antitumor, antiproliferative agent; amidating a 2-aminoindole with an alpha-substituted-beta-hydroxy-alkyl acrylate SANOFI-AVENTIS (FR) 2011-09-06 US disclosed
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics SANOFI-AVENTIS (FR) 2008-09-04 US disclosed
US-7390818-B2 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-06-24 US disclosed
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288318-A1 Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics PNPO, PDXK, PLPBP LMNA 1421/4885NPSR1 2214/4885MEN1 1598/4885
US-20080214538-A1 Pyridoindolone Derivatives Substituted in the 3-Position by a Phenyl, Their Preparation and Their Application in Therapeutics PNPO, PLPBP, DPYD LMNA 1736/4885NPSR1 2694/4885MEN1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.